⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 4, 2011Journal of Clinical OncologyOpen Access

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

Daniel D. Von Hoff Ramesh K. Ramanathan Mitesh J. Borad Daniel A. Laheru Lon Smith Tina E. Wood Ronald L. Korn Neil Desai Vuong Trieu J. L. Mesías Iglesias Hui Zhang Patrick Soon‐Shiong Tao Shi N.V. Rajeshkumar Anirban Maitra Manuel Hidalgo

View Full Paper

Ask AI

Bookmark

Share

Abstract

The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse effects with substantial antitumor activity, warranting phase III evaluation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hoff et al. (2011) studied this question.

synapsesocial.com/papers/69dd54be0644c7b49d40d020 https://doi.org/10.1200/jco.2011.36.5742

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pancreatic CancerReview · 2010 · 2,570 citations
2Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupRCT · 2007 · 3,851 citations
3Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerRCT · 2008 · 434 citations
4Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Human Clinical Trial · 1997 · 5,897 citations
5Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast CancerLate-Phase Clinical Trial · 2005 · 2,155 citations

More related papers

A phase 2 clinical trial of <i>nab</i>‐paclitaxel in previously treated and chemotherapy‐naive patients with metastatic melanoma2009
New Guidelines to Evaluate the Response to Treatment in Solid Tumors2000
Phase I Clinical Trial Design in Cancer Drug Development2000

More from Journal of Clinical Oncology

Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III TrialMon,
Effectiveness of a Multisite Oncology Financial Navigation Intervention: The Lessening the Impact of Financial Toxicity Clinical TrialFri,